Tarsus Pharmaceuticals Inc.

06/29/2026 | Press release | Distributed by Public on 06/29/2026 14:20

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 25, 2026, Tarsus Pharmaceuticals, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). The Company filed its definitive proxy statement for the proposals voted upon at the Annual Meeting with the Securities and Exchange Commission on April 28, 2026 (the "Proxy Statement").
At the close of business on April 27, 2026, the record date of the Annual Meeting, the Company had 43,023,959 shares of common stock outstanding and entitled to vote. The holders of a total of 38,237,214 shares of common stock were present at the Annual Meeting, either in person or by proxy, which total constituted a quorum of the issued and outstanding shares on the record date of the Annual Meeting.
The following proposals were submitted to the Company's stockholders at the Annual Meeting:
1.The election of four nominees as Class III directors to serve until the Company's 2029 annual meeting of stockholders.
2.An advisory vote to approve, on a non-binding basis, the Company's named executive officer compensation.
3.The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
The number of votes cast for and against or withheld and the number of abstentions and broker non-votes with respect to each matter voted upon, as applicable, are set forth below:
1. Board of Directors Election Results
The following nominees were elected to serve as Class III directors for a term that will continue until the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified. The number of votes cast regarding each nominee were as follows:
Director Name Votes For Votes Withheld Broker Non-Votes
Wendy Yarno, MBA 34,398,690 374,956 3,463,568
Andrew Goldberg, M.D. 26,733,789 8,039,857 3,463,568
Scott Morrison 34,225,471 548,175 3,463,568
David E.I. Pyott, MBA 33,612,963 1,160,683 3,463,568
The following directors, in addition to Ms. Yarno, Dr. Goldberg, Mr. Morrison, and Mr. Pyott, will continue to serve as members of the Company's Board of Directors ("Board") until the expiration of their respective terms or until their respective successors have been duly elected and qualified: Bobak Azamian, M.D., Ph.D., Katherine Goodrich, M.D., MHS, Bhaskar Chaudhuri, Ph.D., and William Link, Ph.D.
2. Advisory Vote on Named Executive Officer Compensation
The Company's stockholders approved, on an advisory, non-binding basis, the compensation paid to the Company's named executive officers as disclosed in the Proxy Statement. The number of votes cast regarding the proposal were as follows:
Votes For Votes Against Abstain Broker Non-Votes
34,486,767 238,014 48,865 3,463,568
3. Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm
The Company's stockholders approved the ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The number of votes cast for and against and the number of abstentions for this proposal were as follows (there were no broker non-votes for this proposal):
Votes For Votes Against Abstain
38,219,521 3,651 14,042
Tarsus Pharmaceuticals Inc. published this content on June 29, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 29, 2026 at 20:20 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]